相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis
Grant W. Cannon et al.
JOURNAL OF RHEUMATOLOGY (2014)
Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population
Maxine D. Fisher et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification
Inmaculada de la Torre et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2013)
Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis
Machaon Bonafede et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings
Machaon Bonafede et al.
ADVANCES IN THERAPY (2012)
The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review
Robert J. Moots et al.
RHEUMATOLOGY (2012)
Outcomes of switching anti-TNF drugs in rheumatoid arthritis-a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN)
Liisa M. Virkki et al.
CLINICAL RHEUMATOLOGY (2011)
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
K. Malottki et al.
HEALTH TECHNOLOGY ASSESSMENT (2011)
Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry
Ted R. Mikuls et al.
RHEUMATOLOGY (2011)
Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort
Jie Zhang et al.
ARTHRITIS CARE & RESEARCH (2011)
Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States
Vernon F. Schabert et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients
Chureen T. Carter et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents A Cost-Effectiveness Analysis
Axel Finckh et al.
ANNALS OF INTERNAL MEDICINE (2009)
Differences in Annual Medication Costs and Rates of Dosage Increase Between Tumor Necrosis Factor-Antagonist Therapies for Rheumatoid Arthritis in a Managed Care Population
Daniel A. Ollendorf et al.
CLINICAL THERAPEUTICS (2009)
Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis
Karin Laas et al.
CLINICAL RHEUMATOLOGY (2008)
Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept
Maya H. Buch et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis - Results from a large UK national cohort study
Kimme L. Hyrich et al.
ARTHRITIS AND RHEUMATISM (2007)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged ≥65 years with rheumatoid arthritis
D Weycker et al.
CLINICAL THERAPEUTICS (2005)
Pharmacy data in the VA health care system
MW Smith et al.
MEDICAL CARE RESEARCH AND REVIEW (2003)
分享论文
